Small molecule · developed by Atea Pharmaceuticals
Ruzasvir (also known as AT-038 and MK-8408) is an orally administered agent studied in chronic hepatitis C virus infection, including patients with hepatic cirrhosis.
Summary written with AI from the sources listed at the end of this page.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT05904470 | Phase 2 | Chronic Hepatitis C Virus | Completed | AVIR |
| NCT05731843 | Phase 1 | Healthy Volunteer Study | Completed | AVIR |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
Chronic Hepatitis C VirusHCVHealthy Volunteer StudyHepatic CirrhosisHepatitis CHepatitis C, Chronic
Updated Oct 11, 2026. Something wrong or missing? Report it on the AVIR page.
See AVIR's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
AVIR catalysts and pipeline →